We caught up with Davinder Ramsingh, MD, to talk about the potential of using low-intensity focused ultrasound (LIFU) to open the blood–brain barrier.
- Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery
- Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
- The Future Of Cancer Drug Discovery Is Targeted Immune Activation
- Part 4 cGMP Summaries For Combination Products: Uncovering FDA Expectations
- Unpacking The FDA Draft Guidance On Container Closure Systems
- Turning A Historically Limited Modality Into A Respiratory Drug Opportunity
- Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
- Inquiries In Inhalation, Part 2: Having A Nose For Innovation
ON-DEMAND WEBINARS
See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.
Experts take you through the entire selection process for primary packaging components for lyophilization and provide aspects to consider for all relevant attributes.
Through case studies on modified release, poor solubility, and pediatrics, discover how integrating GMP manufacturing and clinical testing can rapidly accelerate development timelines for even the most challenging of molecules.
Optimize drug delivery by leveraging advanced nanoparticle engineering to dramatically increase small-molecule oral drug loading and enable ultra-high-concentration subcutaneous formulations.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2161651129_elderly pharmacy]( "A Taste Masked And Easily Swallowed Malaria Drug For Elderly Patients")
A Taste Masked And Easily Swallowed Malaria Drug For Elderly PatientsDysphagia impacts treatment compliance and disproportionately affects the elderly. Learn how microencapsulation enabled formulation of a water-soluble powder drives patient adherence.
-
![Multicolored pills-GettyImages-1370358685]( "Solid Form Strategies For Increasing Oral Bioavailability")
Solid Form Strategies For Increasing Oral BioavailabilityOptimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive.
-
![gettyimages-471932801-170667a]( "Pharmaceutical Nanotechnology: What To Know")
Pharmaceutical Nanotechnology: What To KnowHere is what you need to know about the key advantages that pharmaceutical nanotechnology provides in improving drug efficacy and decreasing adverse reactions.
-
![Vaccine injectable vials and syringe GettyImages-1252804942]( "A Step Change In Pharmaceutical Glass Packaging Innovation")
A Step Change In Pharmaceutical Glass Packaging InnovationValor Glass represents a significant, and much needed, step forward for glass innovation. Review the findings and learn how an aluminosilicate formulation can lower your glass vials' extractables profile.
-
![GettyImages-1294339670-lab-cleanroom-PPE-computer-team]( "Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations")
Simultaneous Spray Drying For Combination Dry Powder Inhaler FormulationsThree combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.
-
![Autoinjector-Insulin-Pen-Delivery-Device-GettyImages- 1086688132]( "Is The Autoinjector Dead? The Future Of Patient-Centered Drug Delivery")
Is The Autoinjector Dead? The Future Of Patient-Centered Drug DeliveryAutoinjectors revolutionized drug delivery, but innovation is shifting toward oral, wearable, and alternative platforms. Future focus emphasizes patient experience, sustainability, and broader drug delivery toolkits beyond the autoinjector.
-
![science drug development data iStock-1209661917]( "Is Your Combination Product Drug-Led Or Device-Led?")
Is Your Combination Product Drug-Led Or Device-Led?The $118 billion combination-product market is projected to increase at a CAGR of 8.8%. This article answers the question: “Is this actually a combination product? What do we need to do if it is?”
-
![GettyImages-2036497686-lab-team-collaboration-laboratory-tablet-computer]( "Characterizing The E&L Profile Of Stoppers For Drug Stability")
Characterizing The E&L Profile Of Stoppers For Drug StabilityThe significance of E&L testing lies in its ability to identify potential risks associated with the use of containers and packaging materials in the pharmaceutical industry.
-
![MSglassvials]( "Supporting Complex Manufacturing For Liquid And Lyophilized Drug Products")
Supporting Complex Manufacturing For Liquid And Lyophilized Drug ProductsAseptic fill and finish operations gain efficiency and precision with modular isolator technology, inline weight checks, and lyophilization, which are ideal for mRNA-LNPs and other sensitive modalities.
-
![Singota-DSC03221]( "Developmental Testing Of IV Solutions")
Developmental Testing Of IV SolutionsAs IV-administered drugs proliferate, sponsors must understand the associated regulatory requirements, methodologies for useful/required information, and formulations suitable for administration.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Unpacking The FDA Draft Guidance On Container Closure Systems")
Unpacking The FDA Draft Guidance On Container Closure SystemsIn this article, Fran DeGrazio reflects on the significance of the FDA Draft Guidance on Container Closure Systems, the first update since 1999. DeGrazio places the CCS draft guidance in the current context of science-based and risk-based product development for combination products and other injectable drug product delivery systems. She also addresses the integration of CCS guidance into the development organization’s QMS (Quality Management System).
FREE EBOOK
Why Human Factors Are Critical To Drug Delivery Device Success
In today’s highly competitive biopharma market, successful therapies prioritize the patient experience. Increasingly, patients expect to receive advanced therapies at home or in decentralized care settings, which require delivery methods that are easy to use and comfortable.
This collection explores how drug delivery teams can incorporate patient-centricity across development, from early human factors strategies to modality selection, ensuring safe, effective therapies that translate to real-world care.
